Evidence map›Paper›PMID 42106726›Full record

ArticleBMC ophthalmology2026

Fellow-eye herpes simplex virus type 1 uveitis after intravitreal bevacizumab: a case report.

Maria Carmela Saturno, Oscar Matteo Gagliardi, Maurizio La Cava, Marta Armentano, Ludovico Alisi, Francesca Giovannetti, Danilo Iannetta

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria Carmela SaturnoDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. mariacarmela.saturno@uniroma1.it.
Oscar Matteo GagliardiDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Maurizio La CavaDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Marta ArmentanoDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Ludovico AlisiDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Francesca GiovannettiDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Danilo IannettaDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is widely used for neovascular retinal diseases. Intraocular inflammation is a recognized adverse event and typically occurs in the injected eye. Inflammation in the fellow, uninjected eye is exceptionally rare and may be misinterpreted as sterile immune-mediated inflammation, potentially delaying appropriate treatment. We report a case of polymerase chain reaction (PCR)-confirmed herpes simplex virus type 1 (HSV-1) uveitis presenting in the fellow eye shortly after intravitreal bevacizumab administration. CASE PRESENTATION: An 84-year-old man with well-controlled type 2 diabetes mellitus received intravitreal bevacizumab (1.25 mg) in the left eye for neovascular age-related macular degeneration. Three days later, he developed acute granulomatous anterior uveitis with dense vitritis in the right, uninjected eye, while the treated eye remained quiescent. Best-corrected visual acuity decreased to 20/400. Given the severity of inflammation and limited fundus visualization, viral retinitis was suspected. Empirical systemic valacyclovir and topical corticosteroids were initiated. Aqueous humor PCR detected HSV-1 DNA, confirming herpetic uveitis. Inflammation resolved within 40 days with recovery of visual acuity to 20/20 and no progression to acute retinal necrosis. The patient remained recurrence-free under antiviral prophylaxis at last follow-up.

conclusionsSevere fellow-eye inflammation following intravitreal bevacizumab may reflect viral reactivation rather than sterile inflammation. Early diagnostic evaluation, including aqueous humor PCR when clinically indicated, is essential to guide appropriate therapy and prevent sight-threatening complications.

Indexed as

Angiogenesis InhibitorsBevacizumabEye Infections, ViralHerpes SimplexHerpesvirus 1, HumanUveitisAged, 80 and overDNA, ViralHumansIntravitreal InjectionsMaleAngiogenesis InhibitorsBevacizumabDNA, ViralAnti-VEGFContralateral uveitisHSV-1Intraocular inflammationIntravitreal injection

Identifiers

PMID42106726
PMCPMC13330241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.